Impact of real-world ziprasidone dosing on treatment discontinuation rates in patients with schizophrenia or bipolar disorder
To access this article, please choose from the options below
PII: S0920-9964(09)00442-3
doi:10.1016/j.schres.2009.09.023
© 2009 Elsevier B.V. All rights reserved.
